Đang chuẩn bị liên kết để tải về tài liệu:
A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: Safety and genital symptom analysis

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Toremifene (TOR) is a selective oestrogen receptor modulator (SERM) and has comparable efficacy to that of tamoxifen (TAM) in breast cancer patients. Herein, we compared the safety of TOR to that of TAM in the adjuvant treatment of premenopausal breast cancer. | A prospective randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer Safety and genital symptom analysis

TÀI LIỆU LIÊN QUAN

Exploring prospective student teacher's question on mathematics teaching practice

How far the media of managerial accounting can percept the expectations of current and prospective investors in rationalizing credit and investment decisions: Field study in KSA

Hedge algebras, the semantics of vague linguistic information and application prospective

Perioperative patient outcomes in the African Surgical Outcomes Study: a 7-day prospective observational cohort study

Hydrocortisone relieves the immediate post-operative scrotal edema after inguinal varicocelectomy: A prospective clinical trial

A mini review on pyridoacridines: Prospective lead compounds in medicinal chemistry

Bullied at school, bullied at work: A prospective study

Early prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDAassociated outcomes: A prospective cohort investigation

A method for reporting and classifying acute infectious diseases in a prospective study of young children: TEDDY

Neonatal survival and determinants of mortality in Aroresa district, Southern Ethiopia: A prospective cohort study
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.